Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3F8 + interleukin-2
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
3F8 + interleukin-2 is a combination immunotherapy approach for treating high-risk neuroblastoma. 3F8 is a murine IgG3 monoclonal antibody that specifically targets the ganglioside GD2, which is highly expressed on neuroblastoma cells but has restricted distribution in normal human tissues. The antibody works by binding to GD2, activating complement, and mediating antibody-dependent cell-mediated cytotoxicity (ADCC). Interleukin-2 is an immune system stimulant that enhances the activity of immune cells, particularly natural killer cells, potentially boosting the anti-tumor effects of 3F8. This combination aims to improve outcomes in patients with high-risk neuroblastoma.
- Other names
- m3F8 + interleukin-23F8 MAb + interleukin-2Murine 3F8 monoclonal antibody + interleukin-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)GD2
Beyond the preview
Go deeper on 3F8 + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3F8 + interleukin-2.